Core Points - The company held its third extraordinary general meeting of shareholders on November 3, 2025, with no resolutions being rejected [2][5] - The meeting was convened by the board of directors and chaired by Chairman Li Jiahong, utilizing a combination of on-site and online voting methods [2][5] Group 1: Meeting Details - The meeting was attended by all nine current directors and three supervisors, with the presence of senior management [3][4] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [3][4] - The voting results were deemed legal and valid, in compliance with relevant laws and regulations [5] Group 2: Board Changes - Director Zhang Guodong submitted a resignation letter due to internal work adjustments but will continue as the company's deputy general manager [8][9] - Zhang Guodong was elected as a representative director of the employee board during the ninth fourth employee representative conference held on November 3, 2025 [8][10] - His resignation does not affect the minimum number of board members required by law and will not disrupt the normal operations of the board [9][10] Group 3: Director Profile - Zhang Guodong, born in August 1976, holds a bachelor's degree in clinical medicine and an MBA [12] - He has a history of working in the pharmaceutical industry, including roles at Federal Pharmaceuticals and Eli Lilly, before joining the company in 2005 [12] - As of the announcement date, he holds 264,120 shares of the company, representing 0.01% of the total share capital [12]

Core Viewpoint - Tonghua Dongbao announced the election of Mr. Zhang Guodong as the employee representative director for the 11th board of directors during the 4th employee representative assembly scheduled for November 3, 2025 [2] Group 1 - The 9th Fourth Employee Representative Assembly will be held on November 3, 2025 [2] - Mr. Zhang Guodong has been elected as the employee representative director [2]

证券代码：600867 证券简称：通化东宝 公告编号：2025-077 通化东宝药业股份有限公司 关于公司董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 通化东宝药业股份有限公司（以下简称"公司"）董事会近日收到董事张国 栋先生递交的书面辞职报告，因公司内部工作调整，张国栋先生申请辞去公司董 事的职务。辞职后，张国栋先生继续担任公司副总经理职务。 2025 年 11 月 3 日，公司召开第九届第四次职工代表大会，同意选举张国栋 先生为公司第十一届董事会职工代表董事，任期自公司职工代表大会选举之日起 至公司第十一届董事会任期届满之日止。 一、董事辞职情况 (一) 基本情况 | 姓名 | 离任 职务 | 离任时间 | 原定任期到期日 | 离任 原因 | 是否继续 在上市公 司及其控 股子公司 任职 | 具体职务 | 是否存在 未履行完 毕的公开 承诺 | | --- | --- | --- | --- | --- | --- | --- | --- | | 张国栋 | 董事 | 2 ...

吉林秉责律师事务所 本次股东会由公司董事会召集，会议召开方式为现场投票与网络投票相结合 的方式。 1 关于通化东宝药业股份有限公司 二 0 二五年第三次临时股东会的法律意见书 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共和国 公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，吉林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股份有限公 司（以下简称"公司"）的委托，担任公司 2025 年第三次临时股东会（以下简称 "本次股东会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东会的公告材料，随其他需要公告 的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、商家碧律师出席了公司于 2025 年 11 月 3 日上午 10 时在公司会议室召开的本次股东会，审查了公司提供的与召开 本次股东会有关的文件和资料，并进 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-076 通化东宝药业股份有限公司 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 3 日 (二)股东会召开的地点：公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 599 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 881,399,412 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 45.1362 | 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，公司董事长李佳鸿先生主持会议。会议采用现 场投票和网络投票相结合的表决方式。本次会议的召集、召开符合《公司法》和 《公司章程》的有关规定。 1 (五) ...

Core Viewpoint - The controlling shareholder, Dongbao Group, has announced a share buyback plan for Tonghua Dongbao Pharmaceutical Co., Ltd., expressing confidence in the company's future development and value recognition [1][2]. Summary by Sections Share Buyback Plan - Dongbao Group plans to increase its shareholding in Tonghua Dongbao starting from October 31, 2024, through centralized bidding on the Shanghai Stock Exchange, with a minimum increase of 1% of the total share capital (19,817,341 shares) and a maximum of 2% (39,634,681 shares) [1]. - The implementation period for the buyback plan is from October 31, 2024, to October 30, 2025, without a set price range, depending on stock price fluctuations and overall market trends [1]. Implementation Results - As of October 30, 2025, Dongbao Group has successfully increased its shareholding by 27,801,409 shares, amounting to 228 million yuan, which represents 1.42% of the current total share capital [2]. - The actual increase has exceeded the lower limit of the buyback plan [2]. Additional Information - The buyback plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange listing rules [3]. - The implementation of this buyback plan will not affect the company's shareholding structure or lead to changes in the controlling shareholder [4].

Core Viewpoint - The article highlights the increasing interest and investment from global sovereign wealth funds in the A-share market, driven by changes in the global economic landscape and the Federal Reserve's interest rate cuts [3][8]. Group 1: Sovereign Wealth Fund Holdings - As of the end of Q3, the Abu Dhabi Investment Authority held 24 A-shares with a total market value of 4.214 billion yuan, increasing its holdings in several companies such as Baofeng Energy and Tonghua Dongbao [4][5]. - The Kuwait Investment Authority owned 14 A-shares with a total market value of 3.485 billion yuan, significantly increasing its stake in Dongfang Yuhong [6]. - The Singapore Government Investment Corporation held shares in Huaming Equipment and Bochuan Electronics, with foreign investors owning 25.59% of Huaming Equipment as of October 30 [6][7]. Group 2: Market Outlook - Analysts believe that the A-share market is transitioning to a structure driven by profit growth, supported by policy measures and a favorable valuation environment [8]. - The ongoing technological innovations in China are attracting foreign investors, indicating a potential increase in foreign capital allocation in the Chinese market [8][9]. - The Federal Reserve's recent interest rate cuts are expected to enhance global liquidity, which may support the performance of non-U.S. markets, including A-shares and Hong Kong stocks [9].

Core Insights - Junshi Biosciences, founded in December 2012 and listed on the Shanghai Stock Exchange in July 2020, is a leading domestic innovative drug company focused on monoclonal antibody drug development with strong R&D capabilities and international presence [1] Group 1: Financial Performance - In Q3 2025, Junshi Biosciences achieved revenue of 1.806 billion yuan, ranking 8th among 34 companies in the industry, while the industry leader, Changchun High-tech, reported revenue of 9.807 billion yuan [2] - The company reported a net loss of 674 million yuan, ranking last in net profit among the industry peers, with the industry leader, Tonghua Dongbao, posting a net profit of 1.188 billion yuan [2] - The asset-liability ratio for Q3 2025 was 46.14%, higher than the industry average of 26.88%, while the gross profit margin was 80.65%, exceeding the industry average of 70.17% [3] Group 2: Management and Shareholder Information - Chairman Xiong Jun's salary for 2024 was 3.8333 million yuan, a decrease of 3.2876 million yuan from 2023, while CEO Zou Jianjun's salary increased to 8.9874 million yuan, up by 3.1257 million yuan [4] - As of September 30, 2025, the number of A-share shareholders increased by 15.17% to 35,900, with an average holding of 21,400 circulating A-shares, a decrease of 12.96% [5] Group 3: Product and Market Developments - The core product, Toripalimab injection, generated approximately 1.495 billion yuan in domestic sales in the first three quarters of 2025, reflecting a year-on-year growth of about 40% [5] - The company is advancing its internationalization process and has submitted applications for new indications, with ongoing clinical trials for key products [6]

Core Viewpoint - Dongbao Biological is a leading gelatin and collagen producer in China, with significant technological barriers and a notable market share in the industry [1] Group 1: Business Overview - Dongbao Biological was established on March 12, 1997, and listed on the Shenzhen Stock Exchange on July 6, 2011, with its registered and operational base in Baotou, Inner Mongolia [1] - The company's main business includes the research, production, and sales of gelatin products and low molecular weight collagen, categorized under the pharmaceutical and biological industry [1] Group 2: Financial Performance - For Q3 2025, Dongbao Biological reported revenue of 533 million yuan, ranking 22nd among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was 48.447 million yuan, placing the company 20th in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Dongbao Biological's debt-to-asset ratio was 32.50%, higher than the industry average of 26.88% and improved from 36.68% in the previous year [3] - The company's gross profit margin was 24.53%, an increase from 22.62% year-on-year, but still below the industry average of 70.17% [3] Group 4: Executive Compensation - The chairman, Wang Aiguo, received a salary of 9,600 yuan for 2024, unchanged from the previous year, while the general manager, Liu Fang, earned 745,100 yuan, a decrease of 32,000 yuan from 2023 [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.01% to 20,500, while the average number of circulating A-shares held per shareholder increased by 6.39% to 28,800 [5]

Core Viewpoint - Haofan Bio, a leading company in the peptide synthesis reagent sector, was established in December 2003 and went public on July 12, 2023, in Shenzhen, with its headquarters in Suzhou, Jiangsu Province [1] Group 1: Business Overview - Haofan Bio specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks, with a focus on peptide drugs, innovative drugs, and biopharmaceuticals [1] - The company has a differentiated advantage in technology and customer resources [1] Group 2: Financial Performance - In Q3 2025, Haofan Bio reported revenue of 435 million yuan, ranking 24th among 34 companies in the industry, while the industry leader, Changchun High-tech, had revenue of 9.807 billion yuan [2] - The net profit for the same period was approximately 99.24 million yuan, placing the company 16th in the industry, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Haofan Bio's debt-to-asset ratio was 7.86%, significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The company's gross profit margin was 38.75%, which is below the industry average of 70.17%, suggesting room for improvement in profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.14% to 10,000, while the average number of circulating A-shares held per shareholder increased by 19.09% to 4,200.4 [5] - The fifth largest circulating shareholder, Huatai-PB Health Mixed Fund, increased its holdings by 26,430 shares [5] Group 5: Future Outlook - The company is expected to maintain steady growth, with projected net profits of 166 million, 208 million, and 268 million yuan for 2025 to 2027, respectively, and corresponding EPS of 1.54, 1.93, and 2.48 yuan [5] - Haofan Bio has established a presence in over 1,900 pharmaceutical-related enterprises globally and is actively expanding into the European market [5] - The company is enhancing its production capacity through self-built facilities and acquisitions, with ongoing projects in Anhui and Huai'an expected to resolve capacity issues by mid-2026 [5]